First- and Second-Generation Antipsychotics for Children and Young Adults
Efficacy of Second-Generation Antipsychotics: Placebo Comparisons, by Indication (2 of 3)
Second-generation antipsychotics (SGAs) have been compared to placebo to evaluate the clinical benefit achieved with their use.
In treatment of schizophrenia, SGAs were compared with placebo using the Children’s Global Assessment Scale (CGAS) to measure outcomes in 5 studies of 880 participants. The meta-analytic result for the CGAS score is 4.56 points higher (2.55 to 6.57 points higher) with SGAs. In a meta-analysis of 3 studies of 505 participants, the Clinical Global Impression-Improvement (CGI-I) score is 0.75 points lower (0.38 to 1.12 points lower) with SGAs. In 6 studies of 987 participants, the Positive and Negative Syndrome Scale (PANSS) score is 8.69 points lower (5.61 to 11.76 points lower) with SGAs. The strength of evidence for these findings in treating schizophrenia is moderate.
In a pooled analysis of 2 studies of 54 participants being treated for Tourette’s syndrome, the Yale Global Tic Severity Scale (YGTSS) score is 6.98 points lower (3.62 to 10.34 points lower) with SGAs (risperidone and ziprasidone) when compared with placebo. The strength of evidence for this finding is moderate.
Statistical Abbreviation: 95% CI = 95-percent confidence interval
- Seida J, Schouten J, Mousavi S, et al. First- and Second-Generation Antipsychotics for Children and Young Adults. Comparative Effectiveness Review No. 39 (Prepared by the University of Alberta Evidence-based Practice Center under Contract No. 290-2007-10021). Rockville, MD: Agency for Healthcare Research and Quality; February 2012. AHRQ Publication No. 11(12)-EHC077-EF. Available at www.effectivehealthcare.ahrq.gov/pedantipsych.cfm.
Your slide tray is being processed.